Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Mike Wourms as Chief Operations Officer. This appointment bolsters Genezen’s strategic growth plan and comes at a time of significant momentum for the organization. With over a decade of experience and state-of-the-art viral vector facilities, including the recently acquired 86,000 square foot Lexington, MA site, Genezen partners with innovator companies to develop and manufacture gene and cell therapies – from concept to commercial – on a global scale.
This collaborative effort is focused on leveraging Genezen’s viral vector process development and cGMP manufacturing expertise to advance Seattle Children’s XLA gene therapy program. XLA is a rare primary immunodeficiency condition characterized by abnormally low levels of immunoglobulins, also referred to as antibodies. XLA is an X-chromosome-linked inherited disorder that affects males and is caused by defects in the BTK gene required for B cell generation and function. The inability to produce B cells or the immunoglobulins (antibodies) reduces the body’s ability to fight infection. Infants with XLA may initially appear healthy as they are protected by maternal antibodies during their early months. However, as these maternal antibodies wane, these infants often begin to grapple with severe, recurring bacterial infections affecting various parts of their body, including the ears, lungs, sinuses, and skin, which can pose life-threatening risks.
Read the full article here:
